Benzinga | Sep 9, 2020 07:10AM EDT

REGENXBIO Announces Dosing Of First Patient In Phase II AAVIATE Trial Of RGX-314 For The Treatment Of Wet AMD Using Suprachoroidal Delivery

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ --REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV(r)Technology Platform, today announced that the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjectorfor the treatment of wet age-related macular degeneration (wet AMD). The Company expects to report interim data from the first cohort of this trial by the end of 2020.